Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(12):889-890; doi:10.1093/jnci/93.12.889
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Gromeier, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gromeier, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 12, 889-890, June 20, 2001
© 2001 Oxford University Press

EDITORIAL

Viruses as Therapeutic Agents Against Malignant Disease of the Central Nervous System

Matthias Gromeier

Correspondence to: Matthias Gromeier, M.D., Department of Microbiology, Duke University Medical Center, Durham, NC 27710 (e-mail: grome001@ mc.duke.edu).

Viruses have gained attention in experimental approaches toward antineoplastic therapy. Many of these approaches are directed against malignant glioma, by far the most common malignancy of the central nervous system (CNS). Malignant glioma is almost invariably refractory to available treatment options and hence is associated with exceedingly poor prognosis. The urgent need for novel experimental treatments has rendered malignant glioma a prime target for the development of treatment strategies involving animal viruses.

These strategies use viruses either as mere delivery vehicles for heterologous genetic material ("gene therapy") or as infectious agents with inherent cytotoxic activity ("viral oncolysis"). Oncolytic viruses based on adenovirus (1), herpesvirus (21), . . . [Full Text of this Article]

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
X. Q. Lun, J.-H. Jang, N. Tang, H. Deng, R. Head, J. C. Bell, D. F. Stojdl, C. L. Nutt, D. L. Senger, P. A. Forsyth, et al.
Efficacy of Systemically Administered Oncolytic Vaccinia Virotherapy for Malignant Gliomas Is Enhanced by Combination Therapy with Rapamycin or Cyclophosphamide
Clin. Cancer Res., April 15, 2009; 15(8): 2777 - 2788.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
M. K. Merrill, G. Bernhardt, J. H. Sampson, C. J. Wikstrand, D. D. Bigner, and M. Gromeier
Poliovirus receptor CD155-targeted oncolysis of glioma
Neuro-oncol, July 1, 2004; 6(3): 208 - 217.
[Abstract] [PDF]